Acta Oncologica最新文献_第7页

Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy. 应用新辅助化疗治疗肌肉浸润性膀胱癌的实际数据：对手术并发症和肿瘤疗效的影响。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-02 DOI: 10.2340/1651-226X.2025.42052

Hege S Haugnes, Hakon Kjaeve, Eivind Bjerkaas, Ragnhild Hellesnes, Line Hjelle, Magnus Larsen

{"title":"Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy.","authors":"Hege S Haugnes, Hakon Kjaeve, Eivind Bjerkaas, Ragnhild Hellesnes, Line Hjelle, Magnus Larsen","doi":"10.2340/1651-226X.2025.42052","DOIUrl":"10.2340/1651-226X.2025.42052","url":null,"abstract":"Background and purpose: Recommended treatment of urothelial muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy, but there are challenges with low utilization of NAC. We aimed to evaluate the utilization of NAC, perioperative complications and oncological efficacy in a real-world setting.Patients and methods: All patients operated with radical cystectomy at the University Hospital of North Norway during 2011-2021 for MIBC were included. NAC consisted of three cycles of dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (ddMVAC) every second week. Complications after cystectomy (Clavien-Dindo ≥ grade 3 within 30 days), histopathologic NAC response, cancer recurrence, relapse-free survival (RFS), overall survival (OS) and cause of death were reported.Results: We included 124 patients, median observation time of 4 years. Fifty-nine patients (48%) received NAC. Most common causes for not receiving NAC were age ≥ 75 years (n = 38; 31%), cardiovascular disease (n = 7; 5.6%), and reduced kidney function (n = 6; 4.8%). Overall 34 patients (27%) had a ≥ grade 3 complication. The 5-year actuarial OS rate was higher among patients treated with NAC than those without NAC (67% vs. 45%, p = 0.02). Among NAC-treated patients, 29 (49%) were downstaged to non-muscle invasive stage (≤pT1), and the 5-year actuarial RFS and OS were higher among patients with ≤pT1 in the post-cystectomy specimen than those with ≥ pT2 (92% vs. 35%, and 94% vs. 39%, both p < 0.001).Interpretation: The utilization of NAC was high in this real-world setting. Treatment with ddMVAC with achieved downstaging to ≤pT1 was associated with considerably improved RFS and OS.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"13-21"},"PeriodicalIF":2.7,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postoperative complications and health-related quality of life after oesophageal cancer surgery: a national, population-based cohort study. 食道癌术后并发症和与健康相关的生活质量：一项基于人群的全国性队列研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-27 DOI: 10.2340/1651-226X.2024.41290

Pernilla Lagergren, Asif Johar, Anna Schandl

{"title":"Postoperative complications and health-related quality of life after oesophageal cancer surgery: a national, population-based cohort study.","authors":"Pernilla Lagergren, Asif Johar, Anna Schandl","doi":"10.2340/1651-226X.2024.41290","DOIUrl":"10.2340/1651-226X.2024.41290","url":null,"abstract":"Background and purpose: Surgical resection for oesophageal cancer is technically challenging and associated with a high incidence of complications. This study aimed to assess whether complications influence long-term health-related quality of life (HRQL) in oesophageal cancer survivors.Materials and methods: This nationwide cohort study included 617 patients who underwent oesophagectomy for cancer in Sweden between 2013 and 2021 with a 1-year follow-up. Complications within 30 days of surgery were categorised into (1) with or without, (2) medical or surgical and (3) according to the Clavien-Dindo classification (0-1, 2-3a, 3b-4). HRQL was assessed with European Organisation for Research and Treatment questionnaires and analysed using multivariable linear regression models, proving mean score differences (MSD) with 95% confidence intervals. The MSDs were adjusted for age, sex, education level, comorbidity, tumour histology, tumour stage, surgical technique and neoadjuvant therapy.Results: The cohort included 406 patients who survived at least 1 year after oesophageal cancer surgery. Of these, 273 (68%) had at least one complication in the first 30 postoperative days. Long-term HRQL was comparable between patients with or without complications, with or without medical and surgical complications and between different grades of complication severity.Interpretation: This study suggests that the influence of complications within 30 days of oesophageal cancer surgery on HRQL is minor after 1 year.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"974-981"},"PeriodicalIF":2.7,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015-2020 - a comparison with the cohort from 2004 to 2010. 格陵兰2015-2020年非小细胞肺癌的临床病理特征和治疗结果-与2004 - 2010年队列的比较

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.41078

Dorte S Nørøxe, Simone Frandsen, Malene M Clausen, Thomas I Hansen, Uka W Geisler, Alice J Petersen, Seppo W Langer

{"title":"Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015-2020 - a comparison with the cohort from 2004 to 2010.","authors":"Dorte S Nørøxe, Simone Frandsen, Malene M Clausen, Thomas I Hansen, Uka W Geisler, Alice J Petersen, Seppo W Langer","doi":"10.2340/1651-226X.2024.41078","DOIUrl":"10.2340/1651-226X.2024.41078","url":null,"abstract":"Background and purpose: Lung cancer is the leading cause of cancer-related mortality in Greenland. Since 2004, medical treatment of lung cancer has been available in Greenland. However, both diagnostic work-up and treatment logistics are hampered by the lack of medical services in smaller settlements, the infrastructure, and extreme arctic weather conditions. Clinico-pathological data and assessment of treatment outcome in lung cancer in Greenland have not been carried out since 2015. This study aims to provide an analysis of Greenlandic patients with non-small cell lung cancer (NSCLC) from 2015 to 2020, compared to the cohort from the 2015 study. We focus on diagnostics, patient and treatment characteristics, and survival rates. Additionally, we include new data on treatment-related factors and diagnostic delays. Patients/material: Clinical-, pathological-, genomic data, tuberculosis status and survival were retrieved from the medical journal.Results: A total of 163 patients were identified. Survival had improved in stage I, III, and IV, and early-stage disease was more often diagnosed as compared to the 2015 cohort. Molecular alterations and PD-L1 expressing tumors were comparable between Greenlandic and Danish patients. Diagnostic delay was a major concern.Interpretation: While NSCLC survival in Greenland has improved over the past decade, significant challenges remain. The trend towards diagnosing more stage IA-IIIA patients and the recent improvements in diagnostic and therapeutic options in Greenland are expected to translate into a better prognosis in the coming years. Addressing diagnostic delays and enhancing treatment options are crucial steps toward improving outcomes for NSCLC patients in Greenland.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"958-964"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway. 从试验到实践：挪威黑色素瘤患者的免疫检查点抑制剂治疗。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.41266

Denise Reis Costa, Anna K Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen

{"title":"From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway.","authors":"Denise Reis Costa, Anna K Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen","doi":"10.2340/1651-226X.2024.41266","DOIUrl":"10.2340/1651-226X.2024.41266","url":null,"abstract":"Background and purpose: Norway has one of the highest rates of cutaneous melanoma (CM) incidence and mortality globally. Immune checkpoint inhibitor (ICI) therapy for CM was introduced between 2014 and 2017 to improve treatment and patient prognosis, but knowledge about its clinical usage is limited. This study investigates patient's characteristics and treatment patterns in real-world practice compared to clinical trial results.Material and methods: All adult (≥18) CM patients treated with ICI therapy in Norway from 2014 to 2021 were included, utilizing high-coverage data from multiple national registries to describe patients' health, socioeconomic factors, and treatment management, stratified by first ICI therapy. We compared patient and tumour characteristics with findings from five randomized controlled trials (RCTs).Results: Among 2,083 patients receiving ICI therapy, 975 (47%) received nivolumab as their first treatment in the metastatic setting. Patients on combination therapy were younger and had higher education and income levels compared to those on monotherapy. Overall, real-world patients were older and had a higher incidence of brain metastases than those in RCTs. Approximately, 1 in 5 patients would have been excluded from RCTs due to pre-existing autoimmune diseases. Targeted therapy was the most common secondary systemic treatment after first-line PD-1 inhibitors.Interpretation: This study details ICI therapy in Norway, highlighting differences between real-world ICI users and clinical trial participants, raising questions about the effectiveness of this treatment for patients not eligible for trials.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"965-973"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma. 下咽癌男性患者宫颈肌肉质量和 6 个月存活率的影像评估。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-17 DOI: 10.2340/1651-226X.2024.40481

Jouni Laurén, Harri Keski-Säntti, Antti Mäkitie, Otso Arponen

{"title":"Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma.","authors":"Jouni Laurén, Harri Keski-Säntti, Antti Mäkitie, Otso Arponen","doi":"10.2340/1651-226X.2024.40481","DOIUrl":"10.2340/1651-226X.2024.40481","url":null,"abstract":"Background: A significant proportion of newly diagnosed patients with hypopharyngeal carcinoma (HC) are at risk of early death and may not benefit from cancer treatments. Our objective was to assess whether an image-based evaluation of muscle mass could identify patients at risk of impaired survival.Materials and methods: This retrospective study consisted of male patients diagnosed with HC treated at Helsinki University Hospital between 2005 and 2014 (N = 66). Cross-sectional areas of skeletal muscles at the level of the third cervical vertebra (C3) and at the level of the thoracic aortic apex were analyzed using magnetic resonance images and/or computed tomography images. Survival-based cutoff values for low muscle index values were determined using the receiver operating characteristics curves. Kaplan-Meier analyses and Cox proportional hazard models were used to evaluate the associations between the muscle indexes and survival rates.Results: Several muscle indexes were associated with 6-month and 5-year survival. The 6-month survival rate of males with a low sternocleidomastoid muscle index (cutoff 1.73 cm2/m2) was 66%, as opposed to the 97% survival rate for those with an above-the-cutoff muscle index (hazard ratio 13.0 [95% CI 1.5, 116.6]). In a multivariate Cox model adjusted for age, sex, tumor stage, and grade, lower sternocleidomastoid muscle index was significantly associated with decreased 6-month survival.Interpretation: C3-level muscle indexes, particularly the sternocleidomastoid muscle index, are a promising marker in the identification of patients at risk of early mortality and could add confidence in decision-making when choosing between active and palliative care.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"950-957"},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology. ESHO 2 - 85。热疗作为放射治疗晚期颈淋巴结的辅助治疗：欧洲热疗肿瘤学会的一项随机多中心研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-12 DOI: 10.2340/1651-226X.2024.41035

Jens Overgaard, Olav Dahl, Giorgio Arcangeli

{"title":"ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology.","authors":"Jens Overgaard, Olav Dahl, Giorgio Arcangeli","doi":"10.2340/1651-226X.2024.41035","DOIUrl":"10.2340/1651-226X.2024.41035","url":null,"abstract":"Background and purpose: European Society for Hyperthermic Oncology (ESHO) 2-85 is a multicenter randomized trial investigating hyperthermia (HT) as an adjuvant to radiotherapy (RT) in treatment of locally advanced neck nodes. The trial never fulfilled recruitment and was stopped prematurely, and has not previously been published.Patients and methods: Between January 1987 and February 1993, 64 evaluable neck nodes in 54 patients were included. Tumors were stratified according to institution and nodal size and randomly assigned to receive RT alone (2 Gy/fx, 5 fx/wk) to a total dose of 60-70 Gy, including boost, or the same RT followed once weekly by HT (aimed for 43°C for 60 min). The primary endpoint was persistent complete response (local control).Results and interpretation: Sixty-four tumors in 54 patients were evaluable, with a median observation of 17 months. Thirty-four tumors were randomized to RT alone and 30 to RT+HT. Compliance with RT was good. HT was associated with moderate to severe pain and discomfort in 38% of the treatments. In 57% of the heated patients at least one treatment achieved the target temperature. HT did not significantly increase radiation morbidity. The complete response rate was 53% in the RT versus 80% in the RT+HT group, and 3-year persistent local control rate was 32% for RT alone versus 53% for RT+HT; HR: 0.48 [0.23-0.98]. The ESHO 2-85 study demonstrated that addition of a weekly HT treatment to RT of advanced neck nodes significantly enhanced the persistent tumor control. The results substantiate the potential clinical benefit of hyperthermic oncology.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"943-949"},"PeriodicalIF":2.7,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivering improved survivorship care for people affected by advanced or metastatic cancer. 为晚期或转移性癌症患者提供更好的生存护理。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-09 DOI: 10.2340/1651-226X.2024.42197

Julia Lai-Kwon, Sarah Heynemann, Nicolas Hart, Raymond J Chan, Thomas Smith, Andrea L Smith, Larissa Nekhlyudov, Michael Jefford

引用次数: 0

Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients. Denosumab联合放疗替代手术治疗晚期转移性骨病变和病理性骨折：38例回顾性病例研究

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-12-01 DOI: 10.2340/1651-226X.2024.40977

Mehdy Farhang, Martin Isaksson, Johan Wänman, Richard Löfvenberg, Sead Crnalic

{"title":"Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients.","authors":"Mehdy Farhang, Martin Isaksson, Johan Wänman, Richard Löfvenberg, Sead Crnalic","doi":"10.2340/1651-226X.2024.40977","DOIUrl":"10.2340/1651-226X.2024.40977","url":null,"abstract":"Background and purpose: Pathologic and impending fractures occur in patients with advanced metastatic disease and necessitate surgical interventions with high risk of complications. The aim of this study was to analyze the efficacy of combined treatment with denosumab and radiotherapy as an alternative to surgery in treating bone metastases of the pelvis and extremities.Methods: This retrospective cohort study included 38 patients with impending and pathologic fractures due to carcinoma metastases who received monthly injections of denosumab (120 mg/dose) and radiotherapy. Twenty-three patients received denosumab and single-dose radiotherapy of 8 Gy, and 15 patients received denosumab and fractionated radiotherapy. We assessed pain, radiographic signs of fracture healing, survival and complications.Results: Of the 38 patients 36 experienced pain reduction. Callus formation was observed in 11/17 patients with pathologic fractures, and increased mineralization was found in 12/21 patients with impending fractures. In 23/38 patients, we found both pain reduction and callus formation or increased mineralization. There were no statistically significant differences in treatment outcomes between the patients who received denosumab and single-dose radiotherapy and those who received denosumab and fractionated radiotherapy. The survival rates at 30 days and 1 year were 95% and 56%, respectively.Interpretation: Combined treatment with denosumab and radiotherapy may reduce pain and promote bone healing in patients with metastatic impending and pathologic fractures. In this combined treatment, the effect of single-dose radiotherapy appears to be comparable to that of fractionated regimens.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"932-938"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. 瑞典乳腺癌术后坚持辅助内分泌治疗的情况--一项针对 1 年、3 年和 5 年存活者的全国性队列研究，重点关注地区差异。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.40575

Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson

{"title":"Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences.","authors":"Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson","doi":"10.2340/1651-226X.2024.40575","DOIUrl":"10.2340/1651-226X.2024.40575","url":null,"abstract":"Background and purpose: Adjuvant endocrine treatment (AET) is crucial in early oestrogen receptor (ER)-positive breast cancer (BC), providing reduced recurrence rate and increased overall survival. The aim of this study was to estimate AET adherence rates by age at diagnosis and region in Sweden.Patients and methods: In total, 10,422 women diagnosed with ER-positive BC in 2008-2010 were identified in the Swedish National BC Registry. Information on prescriptions and dispensation of AET was gathered through record linkage to the Swedish Prescription Registry. 1, 3- and 5-year medication possession ratios (MPRs) were calculated. Good adherence was set as MPR ≥ 80%.Results: The 1-, 3- and 5-year AET age-adjusted adherence rates were 94.4, 87.6 and 81.6%, respectively. The 1-, 3- and 5- year adherence rate was significantly highest in the South region (96.2, 90.5 and 86.2%). Regions with an oncologic clinic had higher adherence rate than regions without, 82.8% versus 75.5% at 5-year FU. Women at age 40-64 years (95.6, 89.9 and 84.1%) and 65-74 years at diagnosis (95.7, 89.5 and 84.6%) had significantly higher adherence rate than women ≥ 75 years at diagnosis (89.1, 79.2 and 68.3%).Interpretations: Despite guidelines being national, there were significant differences in adherence between regions in Sweden. As the largest differences were between age groups invited and not invited to mammography screening intervention should focus on women < 40 and ≥ 75 years at diagnosis. Further studies are needed to find strategies to increase overall adherence to AET in early BC.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"901-908"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MELACARE Nurse-led follow-up after early-stage melanoma: protocol and feasibility. MELACARE 早期黑色素瘤术后护士主导的随访：方案和可行性。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.41037

Sara M Hansen, Christoffer Johansen, Magnus P B Obinah, Nadine A Kasparian, Peter Genter, Pernille E Bidstrup, Lisbet R Hölmich

{"title":"MELACARE Nurse-led follow-up after early-stage melanoma: protocol and feasibility.","authors":"Sara M Hansen, Christoffer Johansen, Magnus P B Obinah, Nadine A Kasparian, Peter Genter, Pernille E Bidstrup, Lisbet R Hölmich","doi":"10.2340/1651-226X.2024.41037","DOIUrl":"10.2340/1651-226X.2024.41037","url":null,"abstract":"Background and purpose: We developed the Melacare nurse-led intervention, which combines education in skin self-examination as a resource-conscious approach to detecting recurrence and management of fear of cancer recurrence in patients treated for melanoma. This publication presents the Melacare study protocol and evaluates the feasibility and acceptability of Melacare prior to a larger randomised controlled trial.Material and methods: Feasibility and acceptability of Melacare were evaluated in an intervention-only feasibility study, in which patients attended two nurse-led intervention sessions coupled with an educational booklet. Participants completed patient-reported outcome (PRO) questionnaires at baseline and before each session. After the intervention, participants completed a study-specific feedback questionnaire. Feasibility was evaluated in terms of recruitment, adherence, and attendance. Self-reported outcomes from the study-specific questionnaire on intervention effects were also collected. Results of the feasibility study: Fourteen patients (nine stage IA, five stage IB melanoma) participated. Attendance and recruitment rates were 100%, all participants completed the baseline and PRO questionnaires, and 100% read at least half of the educational booklet. In terms of intervention effects, all patients reported improved knowledge of performing skin self-examination and coping with the fear of cancer recurrence.Interpretation: Results indicate that the Melacare nurse-led intervention is highly feasible and acceptable for use with patients treated for early-stage melanoma. Prior to clinical trial commencement, minor refinements include changing the method of recruiting by telephone and offering.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"909-914"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0